顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > エノキサパリン原薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

エノキサパリン原薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

Enoxaparin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
  • レポートID：
    23507
  • 発表時期：
    2025-09-30
  • レポート形式：
    PDF
  • 産業カテゴリー：
    化学及び材料
  • レポート言語：
    英語、日本語
  • ページ数：
    114
  • 発行会社（調査会社）：
    QYResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=159.00円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界のエノキサパリン原薬市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からエノキサパリン原薬市場を分析し、需要構造と成長特性を明確化します。
エノキサパリン原薬市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、エノキサパリン原薬に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要エノキサパリン原薬市場の統計
2025年世界市場規模：171百万米ドル
2026年世界市場規模：210百万米ドル
2032年予測市場規模：287百万米ドル
2026–2032年予測期間CAGR：5.4%
本レポートはエノキサパリン原薬市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
エノキサパリン原薬市場の主要企業には以下が含まれます：
Hepalink
Yantai Dongcheng Pharmaceutical
Changzhou Qianhong Biopharma
Hebei Changshan Biochemical Pharmaceutical
Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical)
Chongqing Yino Pharma
Chengdu Baiyu Pharmaceutical
Haike Group
Jiangxi Haoran Bio-Pharma
Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical)
Stanex 

製品別
Above 100 IU/mg
Below 100 IU/mg 

アプリケーション別
0.2ml:2000IU
0.4ml:4000IU
0.6ml:6000IU
0.8ml:8000IU
1ml:10000IU
Others 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
エノキサパリン原薬市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
エノキサパリン原薬市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にエノキサパリン原薬市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にエノキサパリン原薬市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、エノキサパリン原薬市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、エノキサパリン原薬市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
エノキサパリン原薬市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●エノキサパリン原薬市場の全体像と成長見通し
エノキサパリン原薬市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がエノキサパリン原薬市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
エノキサパリン原薬産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
エノキサパリン原薬市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からエノキサパリン原薬市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
エノキサパリン原薬市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
エノキサパリン原薬市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
title

Description

The global market for Enoxaparin API was estimated to be worth US$ 171 million in 2024 and is forecast to a readjusted size of US$ 287 million by 2031 with a CAGR of 5.4% during the forecast period 2025-2031.

The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Enoxaparin API cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Enoxaparin API or Enoxaparin Sodium API is a low molecular weight heparin (LMWH) derived through controlled depolymerization of heparin benzyl ester, typically sourced from porcine intestinal mucosa. As an anticoagulant agent, it exhibits potent anti-factor Xa activity with a favorable anti-Xa/anti-IIa ratio, offering enhanced safety and efficacy profiles compared to unfractionated heparin. The API is widely used in the formulation of injectable products for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Enoxaparin Sodium is manufactured in compliance with global pharmacopeial standards (USP, EP, ChP), and is available in various potency specifications to meet regional regulatory and formulation requirements.

Some manufacturers, e.g. Nanjing King-Friend Biochemical Pharmaceutical and Amphastar Pharmaceuticals, manufacture the API for their own preparations production in-house. The report statistic scope excludes the self-use part.

The Enoxaparin Sodium API market has remained robust over recent years, driven by consistent demand in thrombosis prevention, increased global surgical procedures, and the aging population. The COVID-19 pandemic temporarily intensified demand due to its pro-thrombotic complications, leading to a short-term spike in API consumption and pricing. Since 2023, demand has stabilized at a higher baseline, while prices have moderated but remain above pre-pandemic levels due to persistent supply chain constraints and stricter regulatory requirements. The API, derived from porcine intestinal heparin, is heavily reliant on raw material availability, making it vulnerable to supply shocks, especially in China and Brazil. Key global API manufacturers include Qianhong, (Techdow) Hepalink Group, Rovi, Nanjing King-Friend, with China dominating in volume and Europe focusing on high-spec GMP-grade supply. Entry barriers remain high due to the product’s biological complexity, stringent characterization needs, and GMP compliance obligations. Regulatory pressure, environmental scrutiny, and increased biosimilar competition continue to compress margins, particularly in developed markets. Looking ahead, the market is expected to grow steadily in volume, but profitability will hinge on vertical integration, quality differentiation, and supply chain resilience. Innovation in alternative delivery systems, such as oral or long-acting formulations, remains in early development but could reshape the market landscape over the long term.

This report aims to provide a comprehensive presentation of the global market for Enoxaparin API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Enoxaparin API by region & country, by Type, and by Application.

The Enoxaparin API market size, estimations, and forecasts are provided in terms of sales volume (kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enoxaparin API.

Market Segmentation
By Company
    Hepalink
    Yantai Dongcheng Pharmaceutical
    Changzhou Qianhong Biopharma
    Hebei Changshan Biochemical Pharmaceutical
    Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical)
    Chongqing Yino Pharma
    Chengdu Baiyu Pharmaceutical
    Haike Group
    Jiangxi Haoran Bio-Pharma
    Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical)
    Stanex

Segment by Type
    Above 100 IU/mg
    Below 100 IU/mg

Segment by Application
    0.2ml:2000IU
    0.4ml:4000IU
    0.6ml:6000IU
    0.8ml:8000IU
    1ml:10000IU
    Others

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Enoxaparin API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Enoxaparin API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Enoxaparin API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
title

Table of Contents

1 Market Overview
    1.1 Enoxaparin API Product Introduction
    1.2 Global Enoxaparin API Market Size Forecast
        1.2.1 Global Enoxaparin API Sales Value (2020-2031)
        1.2.2 Global Enoxaparin API Sales Volume (2020-2031)
        1.2.3 Global Enoxaparin API Sales Price (2020-2031)
    1.3 Enoxaparin API Market Trends & Drivers
        1.3.1 Enoxaparin API Industry Trends
        1.3.2 Enoxaparin API Market Drivers & Opportunity
        1.3.3 Enoxaparin API Market Challenges
        1.3.4 Enoxaparin API Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered
2 Competitive Analysis by Company
    2.1 Global Enoxaparin API Players Revenue Ranking (2024)
    2.2 Global Enoxaparin API Revenue by Company (2020-2025)
    2.3 Global Enoxaparin API Players Sales Volume Ranking (2024)
    2.4 Global Enoxaparin API Sales Volume by Company Players (2020-2025)
    2.5 Global Enoxaparin API Average Price by Company (2020-2025)
    2.6 Key Manufacturers Enoxaparin API Manufacturing Base and Headquarters
    2.7 Key Manufacturers Enoxaparin API Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Enoxaparin API
    2.9 Enoxaparin API Market Competitive Analysis
        2.9.1 Enoxaparin API Market Concentration Rate (2020-2025)
        2.9.2 Global 5 and 10 Largest Manufacturers by Enoxaparin API Revenue in 2024
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enoxaparin API as of 2024)
    2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Above 100 IU/mg
        3.1.2 Below 100 IU/mg
    3.2 Global Enoxaparin API Sales Value by Type
        3.2.1 Global Enoxaparin API Sales Value by Type (2020 VS 2024 VS 2031)
        3.2.2 Global Enoxaparin API Sales Value, by Type (2020-2031)
        3.2.3 Global Enoxaparin API Sales Value, by Type (%) (2020-2031)
    3.3 Global Enoxaparin API Sales Volume by Type
        3.3.1 Global Enoxaparin API Sales Volume by Type (2020 VS 2024 VS 2031)
        3.3.2 Global Enoxaparin API Sales Volume, by Type (2020-2031)
        3.3.3 Global Enoxaparin API Sales Volume, by Type (%) (2020-2031)
    3.4 Global Enoxaparin API Average Price by Type (2020-2031)
4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 0.2ml:2000IU
        4.1.2 0.4ml:4000IU
        4.1.3 0.6ml:6000IU
        4.1.4 0.8ml:8000IU
        4.1.5 1ml:10000IU
        4.1.6 Others
    4.2 Global Enoxaparin API Sales Value by Application
        4.2.1 Global Enoxaparin API Sales Value by Application (2020 VS 2024 VS 2031)
        4.2.2 Global Enoxaparin API Sales Value, by Application (2020-2031)
        4.2.3 Global Enoxaparin API Sales Value, by Application (%) (2020-2031)
    4.3 Global Enoxaparin API Sales Volume by Application
        4.3.1 Global Enoxaparin API Sales Volume by Application (2020 VS 2024 VS 2031)
        4.3.2 Global Enoxaparin API Sales Volume, by Application (2020-2031)
        4.3.3 Global Enoxaparin API Sales Volume, by Application (%) (2020-2031)
    4.4 Global Enoxaparin API Average Price by Application (2020-2031)
5 Segmentation by Region
    5.1 Global Enoxaparin API Sales Value by Region
        5.1.1 Global Enoxaparin API Sales Value by Region: 2020 VS 2024 VS 2031
        5.1.2 Global Enoxaparin API Sales Value by Region (2020-2025)
        5.1.3 Global Enoxaparin API Sales Value by Region (2026-2031)
        5.1.4 Global Enoxaparin API Sales Value by Region (%), (2020-2031)
    5.2 Global Enoxaparin API Sales Volume by Region
        5.2.1 Global Enoxaparin API Sales Volume by Region: 2020 VS 2024 VS 2031
        5.2.2 Global Enoxaparin API Sales Volume by Region (2020-2025)
        5.2.3 Global Enoxaparin API Sales Volume by Region (2026-2031)
        5.2.4 Global Enoxaparin API Sales Volume by Region (%), (2020-2031)
    5.3 Global Enoxaparin API Average Price by Region (2020-2031)
    5.4 North America
        5.4.1 North America Enoxaparin API Sales Value, 2020-2031
        5.4.2 North America Enoxaparin API Sales Value by Country (%), 2024 VS 2031
    5.5 Europe
        5.5.1 Europe Enoxaparin API Sales Value, 2020-2031
        5.5.2 Europe Enoxaparin API Sales Value by Country (%), 2024 VS 2031
    5.6 Asia Pacific
        5.6.1 Asia Pacific Enoxaparin API Sales Value, 2020-2031
        5.6.2 Asia Pacific Enoxaparin API Sales Value by Region (%), 2024 VS 2031
    5.7 South America
        5.7.1 South America Enoxaparin API Sales Value, 2020-2031
        5.7.2 South America Enoxaparin API Sales Value by Country (%), 2024 VS 2031
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Enoxaparin API Sales Value, 2020-2031
        5.8.2 Middle East & Africa Enoxaparin API Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Enoxaparin API Sales Value Growth Trends, 2020 VS 2024 VS 2031
    6.2 Key Countries/Regions Enoxaparin API Sales Value and Sales Volume
        6.2.1 Key Countries/Regions Enoxaparin API Sales Value, 2020-2031
        6.2.2 Key Countries/Regions Enoxaparin API Sales Volume, 2020-2031
    6.3 United States
        6.3.1 United States Enoxaparin API Sales Value, 2020-2031
        6.3.2 United States Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.3.3 United States Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.4 Europe
        6.4.1 Europe Enoxaparin API Sales Value, 2020-2031
        6.4.2 Europe Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.4.3 Europe Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.5 China
        6.5.1 China Enoxaparin API Sales Value, 2020-2031
        6.5.2 China Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.5.3 China Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.6 Japan
        6.6.1 Japan Enoxaparin API Sales Value, 2020-2031
        6.6.2 Japan Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.6.3 Japan Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.7 South Korea
        6.7.1 South Korea Enoxaparin API Sales Value, 2020-2031
        6.7.2 South Korea Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.7.3 South Korea Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.8 Southeast Asia
        6.8.1 Southeast Asia Enoxaparin API Sales Value, 2020-2031
        6.8.2 Southeast Asia Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.8.3 Southeast Asia Enoxaparin API Sales Value by Application, 2024 VS 2031
    6.9 India
        6.9.1 India Enoxaparin API Sales Value, 2020-2031
        6.9.2 India Enoxaparin API Sales Value by Type (%), 2024 VS 2031
        6.9.3 India Enoxaparin API Sales Value by Application, 2024 VS 2031
7 Company Profiles
    7.1 Hepalink
        7.1.1 Hepalink Company Information
        7.1.2 Hepalink Introduction and Business Overview
        7.1.3 Hepalink Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.1.4 Hepalink Enoxaparin API Product Offerings
        7.1.5 Hepalink Recent Development
    7.2 Yantai Dongcheng Pharmaceutical
        7.2.1 Yantai Dongcheng Pharmaceutical Company Information
        7.2.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
        7.2.3 Yantai Dongcheng Pharmaceutical Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.2.4 Yantai Dongcheng Pharmaceutical Enoxaparin API Product Offerings
        7.2.5 Yantai Dongcheng Pharmaceutical Recent Development
    7.3 Changzhou Qianhong Biopharma
        7.3.1 Changzhou Qianhong Biopharma Company Information
        7.3.2 Changzhou Qianhong Biopharma Introduction and Business Overview
        7.3.3 Changzhou Qianhong Biopharma Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.3.4 Changzhou Qianhong Biopharma Enoxaparin API Product Offerings
        7.3.5 Changzhou Qianhong Biopharma Recent Development
    7.4 Hebei Changshan Biochemical Pharmaceutical
        7.4.1 Hebei Changshan Biochemical Pharmaceutical Company Information
        7.4.2 Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
        7.4.3 Hebei Changshan Biochemical Pharmaceutical Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.4.4 Hebei Changshan Biochemical Pharmaceutical Enoxaparin API Product Offerings
        7.4.5 Hebei Changshan Biochemical Pharmaceutical Recent Development
    7.5 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical)
        7.5.1 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Company Information
        7.5.2 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Introduction and Business Overview
        7.5.3 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.5.4 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Enoxaparin API Product Offerings
        7.5.5 Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Recent Development
    7.6 Chongqing Yino Pharma
        7.6.1 Chongqing Yino Pharma Company Information
        7.6.2 Chongqing Yino Pharma Introduction and Business Overview
        7.6.3 Chongqing Yino Pharma Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.6.4 Chongqing Yino Pharma Enoxaparin API Product Offerings
        7.6.5 Chongqing Yino Pharma Recent Development
    7.7 Chengdu Baiyu Pharmaceutical
        7.7.1 Chengdu Baiyu Pharmaceutical Company Information
        7.7.2 Chengdu Baiyu Pharmaceutical Introduction and Business Overview
        7.7.3 Chengdu Baiyu Pharmaceutical Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.7.4 Chengdu Baiyu Pharmaceutical Enoxaparin API Product Offerings
        7.7.5 Chengdu Baiyu Pharmaceutical Recent Development
    7.8 Haike Group
        7.8.1 Haike Group Company Information
        7.8.2 Haike Group Introduction and Business Overview
        7.8.3 Haike Group Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.8.4 Haike Group Enoxaparin API Product Offerings
        7.8.5 Haike Group Recent Development
    7.9 Jiangxi Haoran Bio-Pharma
        7.9.1 Jiangxi Haoran Bio-Pharma Company Information
        7.9.2 Jiangxi Haoran Bio-Pharma Introduction and Business Overview
        7.9.3 Jiangxi Haoran Bio-Pharma Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.9.4 Jiangxi Haoran Bio-Pharma Enoxaparin API Product Offerings
        7.9.5 Jiangxi Haoran Bio-Pharma Recent Development
    7.10 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical)
        7.10.1 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Company Information
        7.10.2 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Introduction and Business Overview
        7.10.3 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.10.4 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Enoxaparin API Product Offerings
        7.10.5 Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Recent Development
    7.11 Stanex
        7.11.1 Stanex Company Information
        7.11.2 Stanex Introduction and Business Overview
        7.11.3 Stanex Enoxaparin API Sales, Revenue, Price and Gross Margin (2020-2025)
        7.11.4 Stanex Enoxaparin API Product Offerings
        7.11.5 Stanex Recent Development
8 Industry Chain Analysis
    8.1 Enoxaparin API Industrial Chain
    8.2 Enoxaparin API Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Enoxaparin API Sales Model
        8.5.2 Sales Channel
        8.5.3 Enoxaparin API Distributors
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer
title

Table of Figures

List of Tables
 Table 1. Enoxaparin API Market Trends
 Table 2. Enoxaparin API Market Drivers & Opportunity
 Table 3. Enoxaparin API Market Challenges
 Table 4. Enoxaparin API Market Restraints
 Table 5. Global Enoxaparin API Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Enoxaparin API Revenue Market Share by Company (2020-2025)
 Table 7. Global Enoxaparin API Sales Volume by Company (2020-2025) & (kg)
 Table 8. Global Enoxaparin API Sales Volume Market Share by Company (2020-2025)
 Table 9. Global Market Enoxaparin API Price by Company (2020-2025) & (US$/kg)
 Table 10. Key Manufacturers Enoxaparin API Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Enoxaparin API Product Type
 Table 12. Key Manufacturers Time to Begin Mass Production of Enoxaparin API
 Table 13. Global Enoxaparin API Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enoxaparin API as of 2024)
 Table 15. Mergers & Acquisitions, Expansion Plans
 Table 16. Global Enoxaparin API Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 17. Global Enoxaparin API Sales Value by Type (2020-2025) & (US$ Million)
 Table 18. Global Enoxaparin API Sales Value by Type (2026-2031) & (US$ Million)
 Table 19. Global Enoxaparin API Sales Market Share in Value by Type (2020-2025)
 Table 20. Global Enoxaparin API Sales Market Share in Value by Type (2026-2031)
 Table 21. Global Enoxaparin API Sales Volume by Type: 2020 VS 2024 VS 2031 (kg)
 Table 22. Global Enoxaparin API Sales Volume by Type (2020-2025) & (kg)
 Table 23. Global Enoxaparin API Sales Volume by Type (2026-2031) & (kg)
 Table 24. Global Enoxaparin API Sales Market Share in Volume by Type (2020-2025)
 Table 25. Global Enoxaparin API Sales Market Share in Volume by Type (2026-2031)
 Table 26. Global Enoxaparin API Price by Type (2020-2025) & (US$/kg)
 Table 27. Global Enoxaparin API Price by Type (2026-2031) & (US$/kg)
 Table 28. Global Enoxaparin API Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 29. Global Enoxaparin API Sales Value by Application (2020-2025) & (US$ Million)
 Table 30. Global Enoxaparin API Sales Value by Application (2026-2031) & (US$ Million)
 Table 31. Global Enoxaparin API Sales Market Share in Value by Application (2020-2025)
 Table 32. Global Enoxaparin API Sales Market Share in Value by Application (2026-2031)
 Table 33. Global Enoxaparin API Sales Volume by Application: 2020 VS 2024 VS 2031 (kg)
 Table 34. Global Enoxaparin API Sales Volume by Application (2020-2025) & (kg)
 Table 35. Global Enoxaparin API Sales Volume by Application (2026-2031) & (kg)
 Table 36. Global Enoxaparin API Sales Market Share in Volume by Application (2020-2025)
 Table 37. Global Enoxaparin API Sales Market Share in Volume by Application (2026-2031)
 Table 38. Global Enoxaparin API Price by Application (2020-2025) & (US$/kg)
 Table 39. Global Enoxaparin API Price by Application (2026-2031) & (US$/kg)
 Table 40. Global Enoxaparin API Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 41. Global Enoxaparin API Sales Value by Region (2020-2025) & (US$ Million)
 Table 42. Global Enoxaparin API Sales Value by Region (2026-2031) & (US$ Million)
 Table 43. Global Enoxaparin API Sales Value by Region (2020-2025) & (%)
 Table 44. Global Enoxaparin API Sales Value by Region (2026-2031) & (%)
 Table 45. Global Enoxaparin API Sales Volume by Region (kg): 2020 VS 2024 VS 2031
 Table 46. Global Enoxaparin API Sales Volume by Region (2020-2025) & (kg)
 Table 47. Global Enoxaparin API Sales Volume by Region (2026-2031) & (kg)
 Table 48. Global Enoxaparin API Sales Volume by Region (2020-2025) & (%)
 Table 49. Global Enoxaparin API Sales Volume by Region (2026-2031) & (%)
 Table 50. Global Enoxaparin API Average Price by Region (2020-2025) & (US$/kg)
 Table 51. Global Enoxaparin API Average Price by Region (2026-2031) & (US$/kg)
 Table 52. Key Countries/Regions Enoxaparin API Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 53. Key Countries/Regions Enoxaparin API Sales Value, (2020-2025) & (US$ Million)
 Table 54. Key Countries/Regions Enoxaparin API Sales Value, (2026-2031) & (US$ Million)
 Table 55. Key Countries/Regions Enoxaparin API Sales Volume, (2020-2025) & (kg)
 Table 56. Key Countries/Regions Enoxaparin API Sales Volume, (2026-2031) & (kg)
 Table 57. Hepalink Company Information
 Table 58. Hepalink Introduction and Business Overview
 Table 59. Hepalink Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 60. Hepalink Enoxaparin API Product Offerings
 Table 61. Hepalink Recent Development
 Table 62. Yantai Dongcheng Pharmaceutical Company Information
 Table 63. Yantai Dongcheng Pharmaceutical Introduction and Business Overview
 Table 64. Yantai Dongcheng Pharmaceutical Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 65. Yantai Dongcheng Pharmaceutical Enoxaparin API Product Offerings
 Table 66. Yantai Dongcheng Pharmaceutical Recent Development
 Table 67. Changzhou Qianhong Biopharma Company Information
 Table 68. Changzhou Qianhong Biopharma Introduction and Business Overview
 Table 69. Changzhou Qianhong Biopharma Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 70. Changzhou Qianhong Biopharma Enoxaparin API Product Offerings
 Table 71. Changzhou Qianhong Biopharma Recent Development
 Table 72. Hebei Changshan Biochemical Pharmaceutical Company Information
 Table 73. Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
 Table 74. Hebei Changshan Biochemical Pharmaceutical Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 75. Hebei Changshan Biochemical Pharmaceutical Enoxaparin API Product Offerings
 Table 76. Hebei Changshan Biochemical Pharmaceutical Recent Development
 Table 77. Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Company Information
 Table 78. Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Introduction and Business Overview
 Table 79. Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 80. Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Enoxaparin API Product Offerings
 Table 81. Hubei Enoray Biopharmaceutical (Tianjin Chasesun Pharmaceutical) Recent Development
 Table 82. Chongqing Yino Pharma Company Information
 Table 83. Chongqing Yino Pharma Introduction and Business Overview
 Table 84. Chongqing Yino Pharma Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 85. Chongqing Yino Pharma Enoxaparin API Product Offerings
 Table 86. Chongqing Yino Pharma Recent Development
 Table 87. Chengdu Baiyu Pharmaceutical Company Information
 Table 88. Chengdu Baiyu Pharmaceutical Introduction and Business Overview
 Table 89. Chengdu Baiyu Pharmaceutical Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 90. Chengdu Baiyu Pharmaceutical Enoxaparin API Product Offerings
 Table 91. Chengdu Baiyu Pharmaceutical Recent Development
 Table 92. Haike Group Company Information
 Table 93. Haike Group Introduction and Business Overview
 Table 94. Haike Group Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 95. Haike Group Enoxaparin API Product Offerings
 Table 96. Haike Group Recent Development
 Table 97. Jiangxi Haoran Bio-Pharma Company Information
 Table 98. Jiangxi Haoran Bio-Pharma Introduction and Business Overview
 Table 99. Jiangxi Haoran Bio-Pharma Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 100. Jiangxi Haoran Bio-Pharma Enoxaparin API Product Offerings
 Table 101. Jiangxi Haoran Bio-Pharma Recent Development
 Table 102. Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Company Information
 Table 103. Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Introduction and Business Overview
 Table 104. Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 105. Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Enoxaparin API Product Offerings
 Table 106. Shandong Chenlong Pharmaceutical (Cisen Pharmaceutical) Recent Development
 Table 107. Stanex Company Information
 Table 108. Stanex Introduction and Business Overview
 Table 109. Stanex Enoxaparin API Sales (kg), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
 Table 110. Stanex Enoxaparin API Product Offerings
 Table 111. Stanex Recent Development
 Table 112. Key Raw Materials Lists
 Table 113. Raw Materials Key Suppliers Lists
 Table 114. Enoxaparin API Downstream Customers
 Table 115. Enoxaparin API Distributors List
 Table 116. Research Programs/Design for This Report
 Table 117. Key Data Information from Secondary Sources
 Table 118. Key Data Information from Primary Sources


List of Figures
 Figure 1. Enoxaparin API Product Picture
 Figure 2. Global Enoxaparin API Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Enoxaparin API Sales Value (2020-2031) & (US$ Million)
 Figure 4. Global Enoxaparin API Sales Volume (2020-2031) & (kg)
 Figure 5. Global Enoxaparin API Sales Price (2020-2031) & (US$/kg)
 Figure 6. Enoxaparin API Report Years Considered
 Figure 7. Global Enoxaparin API Players Revenue Ranking (2024) & (US$ Million)
 Figure 8. Global Enoxaparin API Players Sales Volume Ranking (2024) & (kg)
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Enoxaparin API Revenue in 2024
 Figure 10. Enoxaparin API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 11. Above 100 IU/mg Picture
 Figure 12. Below 100 IU/mg Picture
 Figure 13. Global Enoxaparin API Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 14. Global Enoxaparin API Sales Value Market Share by Type, 2024 & 2031
 Figure 15. Global Enoxaparin API Sales Volume by Type (2020 VS 2024 VS 2031) & (kg)
 Figure 16. Global Enoxaparin API Sales Volume Market Share by Type, 2024 & 2031
 Figure 17. Global Enoxaparin API Price by Type (2020-2031) & (US$/kg)
 Figure 18. Product Picture of 0.2ml:2000IU
 Figure 19. Product Picture of 0.4ml:4000IU
 Figure 20. Product Picture of 0.6ml:6000IU
 Figure 21. Product Picture of 0.8ml:8000IU
 Figure 22. Product Picture of 1ml:10000IU
 Figure 23. Product Picture of Others
 Figure 24. Global Enoxaparin API Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 25. Global Enoxaparin API Sales Value Market Share by Application, 2024 & 2031
 Figure 26. Global Enoxaparin API Sales Volume by Application (2020 VS 2024 VS 2031) & (kg)
 Figure 27. Global Enoxaparin API Sales Volume Market Share by Application, 2024 & 2031
 Figure 28. Global Enoxaparin API Price by Application (2020-2031) & (US$/kg)
 Figure 29. North America Enoxaparin API Sales Value (2020-2031) & (US$ Million)
 Figure 30. North America Enoxaparin API Sales Value by Country (%), 2024 VS 2031
 Figure 31. Europe Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 32. Europe Enoxaparin API Sales Value by Country (%), 2024 VS 2031
 Figure 33. Asia Pacific Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Enoxaparin API Sales Value by Region (%), 2024 VS 2031
 Figure 35. South America Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 36. South America Enoxaparin API Sales Value by Country (%), 2024 VS 2031
 Figure 37. Middle East & Africa Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 38. Middle East & Africa Enoxaparin API Sales Value by Country (%), 2024 VS 2031
 Figure 39. Key Countries/Regions Enoxaparin API Sales Value (%), (2020-2031)
 Figure 40. Key Countries/Regions Enoxaparin API Sales Volume (%), (2020-2031)
 Figure 41. United States Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 42. United States Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 43. United States Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 44. Europe Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 45. Europe Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 46. Europe Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 47. China Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 48. China Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 49. China Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 50. Japan Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 51. Japan Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 52. Japan Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 53. South Korea Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 54. South Korea Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 55. South Korea Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 56. Southeast Asia Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 57. Southeast Asia Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 58. Southeast Asia Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 59. India Enoxaparin API Sales Value, (2020-2031) & (US$ Million)
 Figure 60. India Enoxaparin API Sales Value by Type (%), 2024 VS 2031
 Figure 61. India Enoxaparin API Sales Value by Application (%), 2024 VS 2031
 Figure 62. Enoxaparin API Industrial Chain
 Figure 63. Enoxaparin API Manufacturing Cost Structure
 Figure 64. Channels of Distribution (Direct Sales, and Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有